Sustained Virologic Response for Chronic Hepatitis C Infection After 27 Days of Treatment with Sofosbuvir and Ribavirin

por Meissner, Eric G., Nelson, Amy, Marti, Miriam, Masur, Henry, Osinusi, Anu, Kottilil, Shyam
Publicado 2014

Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects

por Humeniuk, Rita, Mathias, Anita, Cao, Huyen, Osinusi, Anu, Shen, Gong, Chng, Estelle, Ling, John, Vu, Amanda, German, Polina
Publicado 2020

Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment

por Tang, Lydia Shuk Yee, Masur, Jack, Sims, Zayani, Nelson, Amy, Osinusi, Anu, Kohli, Anita, Kattakuzhy, Sarah, Polis, Michael, Kottilil, Shyam
Publicado 2016

Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineage

por Hostager, Reilly, Ragonnet-Cronin, Manon, Murrell, Ben, Hedskog, Charlotte, Osinusi, Anu, Susser, Simone, Sarrazin, Christoph, Svarovskaia, Evguenia, Wertheim, Joel O
Publicado 2019

Reply to Yan and Muller, “Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver”

por Murakami, Eisuke, Bilello, John, Li, Ruidong, Li, Li, Porter, Danielle, Humeniuk, Rita, Mackman, Richard, Cihlar, Tomas, Osinusi, Anu, Feng, Joy
Publicado 2021

476. Gilead Sciences’ Commitment to the COVID-19 Pandemic

por Lee, EunYoung, Osinusi, Anu, Chokkalingam, Anand, Brainard, Diana M, Tran, Tram, Dau, Lauren, Ferrinho, Diogo, Wang, ChenYu, Juneja, Kavita
Publicado 2020

Multitarget Direct‐Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus

por Shrivastava, Shikha, Bhatta, Manasa, Ward, Haley, Romani, Sara, Lee, Rebecca, Rosenthal, Elana, Osinusi, Anu, Kohli, Anita, Masur, Henry, Kottilil, Shyam, Wilson, Eleanor
Publicado 2018

Immune Biomarker Differences and Changes Comparing HCV Mono-Infected, HIV/HCV Co-Infected, and HCV Spontaneously Cleared Patients

por Kushner, Lauren E., Wendelboe, Aaron M., Lazzeroni, Laura C., Chary, Aarthi, Winters, Mark A., Osinusi, Anu, Kottilil, Shyam, Polis, Michael A., Holodniy, Mark
Publicado 2013

Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes

por Chaturvedi, Nimisha, Svarovskaia, Evguenia S, Mo, Hongmei, Osinusi, Anu O, Brainard, Diana M, Subramanian, G Mani, McHutchison, John G, Zeuzem, Stefan, Fellay, Jacques
Publicado 2019

Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting

por Pan, David Z., Odorizzi, Pamela M., Schoenichen, Andre, Abdelghany, Mazin, Chen, Shuguang, Osinusi, Anu, Patterson, Scott D., Downie, Bryan, Juneja, Kavita, Wallin, Jeffrey J.
Publicado 2023

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor

por Humeniuk, Rita, Mathias, Anita, Kirby, Brian J., Lutz, Justin D., Cao, Huyen, Osinusi, Anu, Babusis, Darius, Porter, Danielle, Wei, Xuelian, Ling, John, Reddy, Y. Sunila, German, Polina
Publicado 2021

Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States

por Chokkalingam, Anand P., Hayden, Jennifer, Goldman, Jason D., Li, Hu, Asubonteng, Julius, Mozaffari, Essy, Bush, Christopher, Wang, Jocelyn R., Kong, Amanda, Osinusi, Anu O., Gottlieb, Robert L.
Publicado 2022

High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study

por Petersen, Tess, Townsend, Kerry, Gordon, Lori A., Sidharthan, Sreetha, Silk, Rachel, Nelson, Amy, Gross, Chloe, Calderón, Monica, Proschan, Michael, Osinusi, Anu, Polis, Michael A., Masur, Henry, Kottilil, Shyam, Kohli, Anita
Publicado 2015

Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants

por Humeniuk, Rita, Juneja, Kavita, Chen, Shuguang, Ellis, Scott, Anoshchenko, Olena, Xiao, Deqing, Share, Aaron, Johnston, Matthew, Davies, Santosh, DeZure, Adam, Llewellyn, Joe, Osinusi, Anu, Winter, Helen, Girish, Sandhya, Palaparthy, Ramesh, Dresser, Mark
Publicado 2023

Real-world Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1

por Ruane, Peter, Buggisch, Peter, Moreno, ANA, Isakov, Vasily, Backus, Lisa, Ain, Dani, Gonzalez-Garcia, Juan, Naik, Sarjita, Mehta, Swarup, Lee, Jina, Llewellyn, Joe, Mertens, Michael, Natha, Macky, Osinusi, Anu, Slim, Jihad, Zhdanov, Konstantin, Berenguer, Juan, Zeuzem, Stefan
Publicado 2017

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

por Shiha, Gamal, Esmat, Gamal, Hassany, Mohamed, Soliman, Reham, Elbasiony, Mohamed, Fouad, Rabab, Elsharkawy, Aisha, Hammad, Radi, Abdel-Razek, Wael, Zakareya, Talaat, Kersey, Kathryn, Massetto, Benedetta, Osinusi, Anu, Lu, Sophia, Brainard, Diana M, McHutchison, John G, Waked, Imam, Doss, Wahid
Publicado 2019

Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study

por Brown, Samuel M., Katz, Morgan J., Ginde, Adit A., Juneja, Kavita, Ramchandani, Monica, Schiffer, Joshua T., Vaca, Carlos, Gottlieb, Robert L., Tian, Yuan, Elboudwarej, Emon, Hill, Joshua A., Gilson, Richard, Rodriguez, Lauren, Hedskog, Charlotte, Chen, Shuguang, Montezuma-Rusca, Jairo M., Osinusi, Anu, Paredes, Roger
Publicado 2023

Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study

por Wei, Lai, Xie, Qing, Hou, Jin Lin, Tang, Hong, Ning, Qin, Cheng, Jun, Nan, Yuemin, Zhang, Lunli, Li, Jun, Jiang, Jianning, McNabb, Brian, Zhang, Fangqiu, Camus, Gregory, Mo, Hongmei, Osinusi, Anu, Brainard, Diana M., Gong, Guozhong, Mou, Zhuangbo, Wu, Shanming, Wang, Guiqiang, Hu, Peng, Gao, Yanhang, Jia, Jidong, Duan, Zhongping
Publicado 2018

72. Remdesivir vs Standard Care in Patients with Moderate covid-19

por Marty, Francisco M, Malhotra, Prashant, Gottlieb, Robert L, Tashima, Karen T, Galli, Massimo, Chai, Louis Yi Ann, SenGupta, Devi, Hyland, Robert H, Wang, Hongyuan, Zhong, Lijie, Cao, Huyen, Chokkalingam, Anand, Osinusi, Anu, Brainard, Diana M, Brown, Michael, Goikoetxea, Ane Josune, Jain, Mamta, Hui, David Shu Cheong, Bernasconi, Enos, Spinner, Christoph
Publicado 2020

LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial

por Hill, Joshua A, Paredes, Roger, Vaca, Carlos, Mera, Jorge, Webb, Brandon J, Perez, Gilberto, Oguchi, Godson, Ryan, Pablo, Gerstoft, Jan, Brown, Michael, Schiffer, Joshua, Brown, Samuel, Katz, Morgan, Ginde, Adit A, Camus, Gregory, Porter, Danielle P, Hyland, Robert H, Chen, Shuguang, Juneja, Kavita, Osinusi, Anu, Duff, Frank, Gottlieb, Robert L
Publicado 2021